In contrast, CD8 + T-cell counts (p = 0.039), FOXP3+ T-cell counts (p = 0.004), and FOXP3+/CD8+  T-cell ratio (p = 0.007) were significantly higher in non-responders than in responders as for post-treatment breast cancers (Fig. 2d–f). This evidence concerns the gene CD8A and breast carcinoma.